Cart
sales@molnova.com
α2β1 Integrin Ligand Peptide
CAS No. 134580-64-6
α2β1 Integrin Ligand Peptide( —— )
Catalog No. M30183 CAS No. 134580-64-6
The Asp-Gly-Glu-Ala (DGEA) amino acid domain of type I collagen interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 259 | Get Quote |
|
| 10MG | 409 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product Nameα2β1 Integrin Ligand Peptide
-
NoteResearch use only, not for human use.
-
Brief DescriptionThe Asp-Gly-Glu-Ala (DGEA) amino acid domain of type I collagen interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.
-
DescriptionThe Asp-Gly-Glu-Ala (DGEA) amino acid domain of type I collagen interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.
-
In Vitroα2β1 Integrin Ligand Peptide (DGEA) (0.015-2.0 mM) inhibits SA11, RRV, and Wa infection in a dose-dependent manner and had no effect on CRW-8 infectivity.α2β1 Integrin Ligand Peptide induces tyrosine kinase-dependent calcium mobilization in osteoblasts and fibroblasts at concentrations of ≥0.5 mM.α2β1 Integrin Ligand Peptide loses its ability to inhibit SA11 binding at 1.0 mM.
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number134580-64-6
-
Formula Weight390.35
-
Molecular FormulaC14H22N4O9
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:{Asp}{Gly}{Glu}{Ala}
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Graham KL, et al. Effects on rotavirus cell binding and infection of monomeric and polymeric peptides containing alpha2beta1 and alphaxbeta2 integrin ligand sequences. J Virol. 2004 Nov;78(21):11786-97.
molnova catalog
related products
-
Natalizumab
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
-
Efalizumab
Efalizumab, a novel potent regulator of T cells, is a humanized LFA-1 α subunit (CD11a) monoclonal antibody.
-
CWHM-12
A novel active RGD peptidomimetic inhibitor of αv integrin with IC50s of 1.8/0.8/61/1.5/0.2 nM for αvβ1/αvβ3/αvβ5/αvβ6/αvβ8; no inhibition on αIIbβ3, α2β1 and α10β1 (>50 uM).
